Evidence map›Paper›PMID 27730374›Full record

ArticleJournal of neurology2016

Importance of cerebrospinal fluid analysis in the era of McDonald 2010 criteria: a German-Austrian retrospective multicenter study in patients with a clinically isolated syndrome.

André M Huss, Steffen Halbgebauer, Patrick Öckl, Corinna Trebst, Annette Spreer, Nadja Borisow, Andrea Harrer, Isabel Brecht, Bettina Balint, Oliver Stich and 19 more

Open access · hybridAbstract readMulticenter Study
In one paragraph

Article in Journal of neurology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed, 1 pooled it
7.9field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 1 synthesis or guideline pooled it, 53 citations in OpenAlex.

  1. Pooled it
  2. Experimental laboratory biomarkers in multiple sclerosis.Wiener medizinische Wochenschrift (1946) · 2022
    Review
  3. Does CSF pleocytosis have a predictive value for disease course in MS?Neurology(R) neuroimmunology & neuroinflammation · 2019
    Article
  4. Observational
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

29 authors at 10 institutions in 3 countries.

André M HussDepartment of Neurology, University of Ulm, Oberer Eselsberg 45, 89081, Ulm, Germany.
Steffen HalbgebauerDepartment of Neurology, University of Ulm, Oberer Eselsberg 45, 89081, Ulm, Germany.
Patrick ÖcklDepartment of Neurology, University of Ulm, Oberer Eselsberg 45, 89081, Ulm, Germany.
Corinna TrebstHannover Medical School, Hannover, Germany.
Annette SpreerUniversity of Göttingen, Göttingen, Germany.
Nadja BorisowNeuroCure Clinical Research Center, Charité-Universitätsmedizin Berlin, Berlin, Germany.
Andrea HarrerDepartment of Neurology, Paracelsus Medical University Salzburg, Salzburg, Austria.
Isabel BrechtUniversity of Würzburg, Würzburg, Germany.
Bettina BalintUniversity of Heidelberg, Heidelberg, Germany.
Oliver StichUniversity of Freiburg, Freiburg, Germany.
Sabine SchlegelDepartment of Neurology, University of Ulm, Oberer Eselsberg 45, 89081, Ulm, Germany.
Nele RetzlaffNeuroimmunological Section, Department of Neurology, University of Rostock, Rostock, Germany.
Alexander WinkelmannNeuroimmunological Section, Department of Neurology, University of Rostock, Rostock, Germany.
Romy RoeslerDepartment of Neurology, University of Ulm, Oberer Eselsberg 45, 89081, Ulm, Germany.
Florian LaudaDepartment of Neurology, University of Ulm, Oberer Eselsberg 45, 89081, Ulm, Germany.
Özlem YildizHannover Medical School, Hannover, Germany.
Elke VoßHannover Medical School, Hannover, Germany.
Rainer MucheDepartment of Neurology, University of Ulm, Oberer Eselsberg 45, 89081, Ulm, Germany.
Sebastian RauerUniversity of Freiburg, Freiburg, Germany.
Florian Then BerghUniversity of Leipzig, Leipzig, Germany.
Markus OttoDepartment of Neurology, University of Ulm, Oberer Eselsberg 45, 89081, Ulm, Germany.
Friedemann PaulNeuroCure Clinical Research Center, Charité-Universitätsmedizin Berlin, Berlin, Germany.
Brigitte WildemannUniversity of Heidelberg, Heidelberg, Germany.
Jörg KrausDepartment of Laboratory Medicine, Paracelsus Medical University Salzburg, Salzburg, Austria.
Klemens RuprechtDepartment of Neurology and Clinical and Experimental Multiple Sclerosis Research Center, Charité-Universitätsmedizin Berlin, Berlin, Germany.
Martin StangelHannover Medical School, Hannover, Germany.
Mathias ButtmannUniversity of Würzburg, Würzburg, Germany.
Uwe K ZettlNeuroimmunological Section, Department of Neurology, University of Rostock, Rostock, Germany.
Hayrettin TumaniDepartment of Neurology, University of Ulm, Oberer Eselsberg 45, 89081, Ulm, Germany. hayrettin.tumani@uni-ulm.de.
Universität Ulm · DEMedizinische Hochschule Hannover · DECharité - Universitätsmedizin Berlin · DEUniversity of Rostock · DEHeidelberg University · DEParacelsus Medical University · ATUniversity of Freiburg · DEUniversity of Würzburg · DELeipzig University · DEUniversity of Göttingen · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The majority of patients presenting with a first clinical symptom suggestive of multiple sclerosis (MS) do not fulfill the MRI criteria for dissemination in space and time according to the 2010 revision of the McDonald diagnostic criteria for MS and are thus classified as clinically isolated syndrome (CIS). To re-evaluate the utility of cerebrospinal fluid (CSF) analysis in the context of the revised McDonald criteria from 2010, we conducted a retrospective multicenter study aimed at determining the prevalence and predictive value of oligoclonal IgG bands (OCBs) in patients with CIS. Patients were recruited from ten specialized MS centers in Germany and Austria. We collected data from 406 patients; at disease onset, 44/406 (11 %) fulfilled the McDonald 2010 criteria for MS. Intrathecal IgG OCBs were detected in 310/362 (86 %) of CIS patients. Those patients were twice as likely to convert to MS according to McDonald 2010 criteria as OCB-negative individuals (hazard ratio = 2.1, p = 0.0014) and in a shorter time period of 25 months (95 % CI 21-34) compared to 47 months in OCB-negative individuals (95 % CI 36-85). In patients without brain lesions at first attack and presence of intrathecal OCBs (30/44), conversion rate to MS was 60 % (18/30), whereas it was only 21 % (3/14) in those without OCBs. Our data confirm that in patients with CIS the risk of conversion to MS substantially increases if OCBs are present at onset. CSF analysis definitely helps to evaluate the prognosis in patients who do not have MS according to the revised McDonald criteria.

Indexed as

Severity of Illness IndexAdultAustriaDisease ProgressionFemaleGermanyHumansKaplan-Meier EstimateMagnetic Resonance ImagingMaleMiddle AgedMultiple SclerosisOligoclonal BandsRetrospective StudiesOligoclonal BandsBiomarkerCSFMultiple sclerosisOCB

Identifiers

PMID27730374
PMCPMC5110610
OpenAlexW2530971761

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.